Sun Pharma Advanced Research Company Ltd Financials
Company Logo

Sun Pharma Advanced Research Company Ltd Financial Statement

Sun Pharma Advanced Research Company Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue12.90
Operating Expense116.71
Net Profit-107.69
Net Profit Margin-834.81
Earning Per Share-3.32
EBIDTA-103.81
Effective Tax RateTBA

Sun Pharma Advanced Research Company Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual75.55
Operating Expenses Annual479.34
Operating Profit Annual-374.32
Interest Annual1.66
Depreciation12.13
Net Profit Annual-388.11
Tax AnnualTBA

Sun Pharma Advanced Research Company Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.58
Cash Flow from Operations-429.43
Cash Flow from Investing391.11
Cash Flow from Financing42.80
Cash Flow at the End5.06

Sun Pharma Advanced Research Company Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-495.46
PBIT Margin (%)-511.52
PBT Margin (%)-203.38
Net PROFIT Margin (%)-513.71
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-82.19
Total Debt / Equity (X)0.11
Asset Turnover Ratio (%)0.16

Sun Pharma Advanced Research Company Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual145.17
Total Current Assets Annual246.41
Non Current Assets Annual239.93
Total Shareholders Funds Annual124.86
Total Assets Annual486.33

Sun Pharma Advanced Research Company Ltd Earning Calls

EPS (INR)

Expected

-3.31

Reported

-3.31

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Sun Pharma Advanced Research Company Ltd has a market capitalization of 12,005.68 Cr. Value Research classifies it as a Large-Cap company.
Yes, Sun Pharma Advanced Research Company Ltd is debt-free with a debt-to-equity ratio of 0.45.
In FY 2023 , Sun Pharma Advanced Research Company Ltd recorded a total revenue of approximately 75.55 Cr marking a significant milestone in the company's financial performance.
Sun Pharma Advanced Research Company Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.3% annually, respectively..
Sun Pharma Advanced Research Company Ltd's current PE ratio is -30.93.
Sun Pharma Advanced Research Company Ltd's ROCE averaged -92.0% from the FY ending March 2022 to 2024, with a median of -107.2%. It peaked at -33.3% in March 2023, reflecting strong capital efficiency over the period..
Sun Pharma Advanced Research Company Ltd's latest EBIT is Rs. -386.45 Cr, surpassing the average EBIT of Rs. -263.82 Cr over the 5 years..